AstraZeneca will pay up to US$6 billion to Japan’s Daiichi Sankyo under the drugmakers’ second multi-billion dollar oncology collaboration to develop and market a niche type of targeted cancer treatment.
AstraZeneca bets up to US$6 billion on new Daiichi cancer drug
